KRAS and cancer: In mini‐CDX models, 10 mg/kg THZ1 distinctly suppressed CAPAN2 (KRAS‐G12V) cancer cells, evident through both significantly reduced RFU and T/C (%) values compared with the vehicle control group on day 7 (p = .022; Figure 2E).